







Domestic dogs cause over

99%

of human rabies deaths.

Nearly

85%

of the world is at risk of contracting canine rabies.



occur in Africa and Asia.

100%
of human cases are
preventable.




Vaccinating

**70%** 

of dogs in at-risk areas can eliminate canine rabies.





Access factors?

Vaccine demand? (for animals and humans)

How many dogs?


How many bite cases?

How many exposures?

How many deaths?

Cost-efficiency of interventions?

# Rabies surveillance situation in Africa



**Fig. 2.** The effectiveness of rabies surveillance globally. Legend: green = human rabies is notifiable and surveillance is effective; orange = human rabies is notifiable, but surveillance is ineffective; grey/green striped = human rabies is notifiable, but no information on effectiveness was supplied; red = human rabies is not notifiable; grey = no survey data available.

Taylor et al. 2015; Surveillance of Human Rabies by National Authorities – A Global Survey; Zoonoses and Public Health

# Human rabies transmitted by dogs: current status of global data, 2015 published in January 2016 in WHO's Weekly Epidemiological Record.

African Region – Région africaine	A1	A2	B1	B2	B3	B4	C1	C2
Algeria – Algérie	7			7			22	67
Angola				91		151	185	458
Benin – Bénin				Unknown – Inconnu	7		178	47
Botswana				Unknown – Inconnu	0		3	2
Burkina Faso				21	8		880	305
Burundi				Unknown - Inconnu			550	278
Cameroon – Cameroun					4		196	203
Central African Republic – République centrafricaine				Unknown – Inconnu	8		227	48
Chad – Tchad				Unknown – Inconnu			64	861
Congo					5		20	18
Côte d'Ivoire				Unknown – Inconnu	15		569	412
Democratic Republic of the Congo — République démocratique du Congo				22	230		5 579	752

- A) Official national reporting to WHO
- B) National data officially displayed or reported elsewhere
- C) Estimates from burden of disease modelling

# → Disconnect between reported data and the actual incidence of rabies

# The GAVI learning agenda on rabies

## Funding for improved data collection and modelling

- Data collection in 8 African and 6 Asian countries + Haiti
- Goal: Inform GAVI advisory board on a vaccine investment strategy!


#### **Swiss TPH contribution:**

- data from Mali, Chad, Côte d'Ivoire and Liberia
- part of the modelling consortium
- participation at WHO expert advisory meeting

## **Swiss TPH core project partners:**

Mali: Laboratoire Centrale Veterinaire (LCV), Dr. Abdallah Traore

Côte d'Ivoire: Centre Suisse de Recherche Scientifique (CSRS), Prof. Bassirou Bonfoh Chad: Centre de Support en Santé International (CSSI), Dr. Daugla Doumagoum Moto Institute de Recherche en Elevage pour le Developpement (IRED), Dr. Richard Ngandolo



#### **Data collection:**

Cross-sectional household survey 2x phone follow-up (8000HH/country)


Longitudinal health facility study registering bite cases

- 1052 Chad
- 3367 Côte d'Ivoire
- 4010 Mali

Longitudinal animal surveillance study


- Chad: 175 positive of 191
- Mali: 57 positive of 67
- Côte d'Ivoire: 29 positive of >700 observations

# Bite cases observed during the baseline household survey




## Estimation of national annual number of bite cases

With annual bite case incidence/1000 person and % coverage



# Estimated vaccine demand compared to current use

Change to 3 dose ID schedule will bring a 60% demand reduction



# The potential effect of improved provision of rabies post-exposure prophylaxis in Gavi-eligible countries: a modelling study



WHO Rabies Modelling Consortium\*



#### **Summary**

Background Tens of thousands of people die from dog-mediated rabies annually. Deaths can be prevented through post-exposure prophylaxis for people who have been bitten, and the disease eliminated through dog vaccination. Current post-exposure prophylaxis use saves many lives, but availability remains poor in many rabies-endemic countries due to high costs, poor access, and supply.

Methods We developed epidemiological and economic models to investigate the effect of an investment in post-exposure prophylaxis by Gavi, the Vaccine Alliance. We modelled post-exposure prophylaxis use according to the status quo, with improved access using WHO-recommended intradermal vaccination, with and without rabies immunoglobulin, and with and without dog vaccination. We took the health provider perspective, including only direct costs.

#### Lancet Infect Dis 2018

Published Online November 21, 2018 http://dx.doi.org/10.1016/ S1473-3099(18)30512-7

See Online/Comment http://dx.doi.org/10.1016/ S1473-3099(18)30606-6

\*Contributors are listed in the appendix

- ✓ Status quo: 1 million deaths occurring from 2020-2035.
- ✓ Free access to PEP will potentially prevent 489'000 deaths
- ✓ With switch to 3 dose ID schedule vaccine demand will not increase
- ✓ Investment of \$635 per death averted

# Anticipated challenges

Difference to other childhood vaccination schemes

- → demand for novel distribution strategies
- → availability at the right time at the right place!

Vaccine preposition currently not useful for ID injection

- → dose reduction per vial needed
- → different syringe and needle

Weak national health and veterinary systems

- → demand for infrastructure support
- → demand for staff training

Health seeking of bite victims

- → Awareness needs to be increased
- → Need for folllow-up to ensure compliance

# Study contribution

Comparison of decentralized and centralized approaches


Estimate of vaccine wastage in Côte d'Ivoire

Increased surveillance through a rapid test

KAP study in human and veterinary workers (Chad)

Free hotline established in Chad

# Access to free PEP will not prevent all human deaths!



## Estimate from our study:

Only max. 40% of bite cases are suspicious of rabies!

Only max. 10% of bites cases are true exposures!



## Core project partners:









## Collaborating national institutions:











## Funding:







## Other partners:





